Results 91 to 100 of about 13,979 (215)

Additional file 3 of TRIM38 triggers the ubiquitination and degradation of glucose transporter type 1 (GLUT1) to restrict tumor progression in bladder cancer

, 2021
Additional file 3: Table S3.
Ning Zhang (23771), Xin Xie (311744), Wenbin Rui (11838546), Xiaojing Wang (147040), Yu Zhu (250261), Hongchao He (3864172)   +5 more
core   +1 more source

HierAnom‐Path: Zero‐Shot Rare Cancer Detection in Histopathology via Hierarchical Foundation Model Adaptation

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Rare cancers collectively represent 20%–25% of all malignancies yet yield fewer than 50 annotated whole‐slide images (WSIs) per subtype in publicly available archives, rendering supervised deep learning inapplicable. We present HierAnom‐Path, to the best of our knowledge, the first framework for zero‐shot rare cancer anomaly detection in ...
Noora Saleem Jumaah, Mohanad Sameer Jabbar, Saif H. Alwaeli, Noor Ayesha, Mohamed Babiker A. Mohamed, Muhammad I. Khan   +5 more
wiley   +1 more source

Table_1_Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer.xlsx

, 2023
RationaleRNA modifications, containing m6A, m1A, alternative polyadenylation and adenosine-to-inosine RNA editing, involve in critical cancerous immunity and cancerous processes. However, the functional roles of RNA modification writers in bladder cancer
Wen Wen (596162), Ying Chen (9697), Yao Zhang (134381)   +2 more
core   +1 more source

Circular RNA circERBB2 Promotes Tumorigenesis via the miR‐1587/CBX2 Axis and Epigenetic Silencing of PTEN in Bladder Cancer Cells

MedComm – Oncology, Volume 5, Issue 4, December 2026.
circERBB2, originating from backsplicing of ERBB2 pre‑mRNA, is robustly upregulated in bladder cancer (BLCA) and acts as a miR‑1587 sponge to derepress chromobox 2 (CBX2). CBX2 subsequently recruits EZH2 to catalyze H3K27me3 deposition at the PTEN promoter, epigenetically silencing this tumor suppressor and unleashing the PI3K/AKT/mTOR cascade to drive
Xiang Pan, Xi Chen, Kailai Chen, Feng Pei, Li Zhong, Yunqi Li, Wenchao Shi, Jian Ma, Yakun Luo   +8 more
wiley   +1 more source

Table1_A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts.XLSX

, 2023
Background: Although the durable efficacy of immune checkpoint inhibitors (ICIs) in BLCA has been confirmed in numerous studies, not all patients benefit from their application in the clinic.
Huihuang Li (1701952), Xiaowen Li (317720), Tiezheng Qi (11271606), Yuanqing Dai (15407567), Neng Liu (2118667), Dingshan Deng (8910740)   +5 more
core   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Image3_A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts.TIF

, 2023
Background: Although the durable efficacy of immune checkpoint inhibitors (ICIs) in BLCA has been confirmed in numerous studies, not all patients benefit from their application in the clinic.
Huihuang Li (1701952), Xiaowen Li (317720), Tiezheng Qi (11271606), Yuanqing Dai (15407567), Neng Liu (2118667), Dingshan Deng (8910740)   +5 more
core   +1 more source

Combining value and vulnerability of pinyon–juniper ecosystems for climate‐smart management: A case study in Black Canyon of the Gunnison National Park

Ecological Solutions and Evidence, Volume 7, Issue 4, October–December 2026.
We develop and demonstrate a new framework for land management in the context of climate transition which incorporates vegetation vulnerability as well as human‐value scores. We apply this framework to pinyon‐juniper conservation in Black Canyon of the Gunnison National Park. Abstract Land management and natural resource conservation involve assessment
Julie Sherman, Carolyn Lober, David Thoma, Michael T. Tercek, Danguole B. Bockus, Seth M. Munson   +5 more
wiley   +1 more source

Source code for ferroptosis gene set activity analysis in BLCA epithelial cells

<p>Source code for ferroptosis gene set activity analysis in BLCA epithelial cells </p ...
Zhang, Yi
core   +1 more source

Deubiquitylase USP52 Promotes Bladder Cancer Progression by Modulating Ferroptosis through Stabilizing SLC7A11/xCT

Advanced Science
Bladder cancer (BLCA) is a prevalent cancer with high case‐fatality rates and a substantial economic burden worldwide. Understanding its molecular underpinnings to guide clinical management is crucial. Ferroptosis, a recently described non‐apoptotic form
Jianmin Liu, Yongwen Luo, Siming Chen, Gang Wang, Wan Jin, Wenyu Jiang, Mingxing Li, Yejinpeng Wang, Jingtian Yu, Houyi Wei, Renjie Zhang, Fenfang Zhou, Lingao Ju, Yi Zhang, Yu Xiao, Kaiyu Qian, Xinghuan Wang   +16 more
doaj   +1 more source